Stockreport

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

Gain Therapeutics, Inc.  (GANX) 
PDF Interim analysis of Phase 1b clinical study of GT-02287, including biomarker and clinical endpoints, will be presented in oral symposium Company remains on track to ini [Read more]